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Dysbiosis in a canine model of human fistulizing Crohn’s disease
Ana Maldonado-Contreras a, Lluís Ferrerb*, Caitlin Cawleya, Sarah Crainb#, Shakti Bhattaraia, Juan Toscanoa&, 
Doyle V. Ward a, and Andrew Hoffmanb$
aDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA, USA; bCummings School 
of Veterinary Medicine, Tufts University, North Grafton, MA, USA
ABSTRACT
Crohn’s disease (CD) is a chronic immune-mediated inflammatory condition caused by the loss of 
mucosal tolerance toward the commensal microbiota. On average, 29.5% and 42.7% CD patients 
experience perianal complications at 10 and 20 y after diagnosis, respectively. Perianal CD (pCD) 
result in high disease burden, diminished quality of life, and elevated health-care costs. Overall pCD 
are predictors of poor long-term outcomes. Animal models of gut inflammation have failed to fully 
recapitulate the human manifestations of fistulizing CD. Here, we evaluated dogs with spontaneous 
canine anal furunculosis (CAF), a disease with clinical similarities to pCD, as a surrogate model for 
understanding the microbial contribution of human pCD pathophysiology.
By comparing the gut microbiomes between dogs suffering from CAF (CAF dogs) and healthy 
dogs, we show CAF-dog microbiomes are either very dissimilar (dysbiotic) or similar (healthy-like), 
yet unique, to healthy dog’s microbiomes. Compared to healthy or healthy-like CAF microbiomes, 
dysbiotic CAF microbiomes showed an increased abundance of Bacteroides vulgatus and Escherichia 
coli and a decreased abundance of Megamonas species and Prevotella copri.
Our results mirror what have been reported in previous microbiome studies of patients with CD; 
particularly, CAF dogs exhibited two distinct microbiome composition: dysbiotic and healthy-like, 
with determinant bacterial taxa such as E. coli and P. copri that overlap what it has been found on 
their human counterpart. Thus, our results support the use of CAF dogs as a surrogate model to 
advance our understanding of microbial dynamics in pCD.
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Introduction
Inflammatory bowel diseases (IBD), including 
Crohn’s disease (CD), are immune-mediated inflam-
matory condition affecting more than a million indi-
viduals in the US. On average, 29.5% and 42.7% CD 
patients experience perianal complications at 10 and 
20 y after diagnosis, respectively.1,2 Perianal Crohn’s 
disease, or pCD, represents one of the most clinically 
significant complications and is a predictor of poor 
long-term outcome in CD.3 Perianal fistulas are 
most common in patients suffering from colonic 
CD with rectal involvement (L2). The etiology of 
pCD is not well defined yet is thought to be 
a combination of genetic and immune factors, and 
the microbiome. Several genetic variants have been 
also associated with increased risk of development of 
pCD, specifically PRDM1, NOD2, and ATG16L1.4,5 
Immunologically, patients with pCD exhibit an up- 
regulated expression of TNF-α compared to CD 
patients without perianal complications or healthy 
controls.6 The role of the microbiome has gained 
attention in recent years as evidence indicating its 
involvement emerges.7–9 Particularly, treatment with 
antibiotics (reviewed in2,10), fecal diversion,7,8 and 
fecal transplants9 have proven to be effective for 
managing the disease. Definition of the pathogenesis 
and pathophysiology of pCD is key to further 
advance treatment strategies for patients. One of 
the main challenges of pCD research is the lack of 
a relevant, reliable, and reproducible animal model. 
Here, we aim to evaluate the usefulness of dogs as 
a model system to elucidate the contribution of the 
microbiota to the pathophysiology of pCD.
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We have postulated that canine anal furunculosis 
(CAF) can be used as a model for studying the 
pathophysiology and treatment of pCD.11,12 CAF 
and pCD exhibit common clinical signs such as 
focal or multifocal dissecting sinus tracts (external 
openings) and ulcerations on the perianal area. The 
American Gastroenterological Association pro-
posed a classification of “simple” and “complex” 
fistulas13 in pCD. Simple fistulas include superficial, 
intersphincteric, or intrasphincteric fistulas below 
the dentate line, with a single tract, and absence of 
perianal complications. Complex fistulas stretch 
above the dentate line (intersphincteric, trans-
phincteric, extrasphincteric, suprasphincteric), 
with many tracts, and may be related to perianal 
abscesses, rectal stricture, proctitis, or can extend to 
the bladder or vagina.1,14 Similarly, CAF includes 
epithelial-lined single or multiple (such as complex 
fistulas in pCD) tracts that develop in the perianal 
tissue including superficial, intersphincteric, or 
intrasphincteric fistulas that can extend to the rectal 
lumen15,16 but not to other areas (compared to 
simple fistulas in pCD).
Treatment for both CAF and pCD requires 
a combination of immunosuppressive drugs (i.e., 
cyclosporin, and tacrolimus),17 adjuvant antibiotic 
therapy, and/or surgery (i.e., fistulectomy, fistulot-
omy, drainage). Cyclosporin has been effective in 
managing both pCD and CAF with up to 78% and 
100% of human (reviewed18) and dogs (reviewed19) 
responding to treatment, respectively. In addition, 
positive clinical response to tacrolimus is similar in 
pCD18 and dogs with CAF19 (44–78% and 50%, 
respectively). Antimicrobials alone do not seem 
effective for the management of pCD nor for CAF. 
In humans, antibiotics are administrated as initial 
treatment or in combination with other therapies 
such as immunosuppressants.2 A few studies have 
reported the use of metronidazole in combination 
with other therapies (azathioprine, tacrolimus oint-
ment, prednisone) for the treatment of CAF.20,21
Treatment with diet for both pCD and CAF is still 
in debate. A dietary guidance for patients with IBD has 
been recently published highlighting the lack of strong 
evidence for foods to include or avoid for patients with 
IBD.22 Most IBD-friendly whole food diets involved 
exclusion of carbohydrates, inclusion of lean protein, 
fruits, and vegetables.23–25 Similarly, few studies have 
demonstrated adverse reaction of foods in some dogs 
with CAF.21,26-28 Dietary treatment with “novel pro-
tein” -refer to foods with protein sources not con-
sumed before by the dog with CAF- such as venison, 
lamb, fish, bison, duck-show modest results in CAF 
treatment when used in combination with immuno-
suppressants, antibiotics, and/or surgery.21,26-28
Despite of having positive clinical responses to 
the aforementioned treatments, the majority of both 
pCD and CAF patients experience relapses of the 
perinal manifestations.
Of note, the German Shepherd Dog (GSD) appears 
to be overrepresented within the population of dogs 
with CAF, with more than 80% of dogs suffering from 
CAF (CAF dogs) being GSD.29,30 GSD is also suscep-
tible to inflammatory bowel disease (IBD),31,32 sys-
temic aspergillosis,33–36 and deep pyoderma,37,38 
suggesting that GSD might have a broadly dysfunc-
tional immune response to microbial exposure at 
epithelial surfaces, similar to human CD patients. 
Dogs have already proven useful for studying various 
other spontaneously occurring disorders similar to 
those affecting humans,11,39-42 and the dog micro-
biome is more similar to that of humans than it is to 
the microbiomes of other animals that are generally 
used as models of microbiome-centered diseases such 
as IBD (e.g., mice and pigs).43 Dogs also sponta-
neously develop IBD31 and can experience common 
disease complications, including perianal fistulas,16 
and exhibit IBD-associated microbiome alterations 
that resemble changes observed in humans with 
IBD.44,45 Thus, dogs represent an ideal model for 
studying IBD and in particular pCD.
Given that the intersection of immunity and the 
microbiota seems to be at the heart of both pCD 
and CAF, we sought to explore naturally occurring 
CAF as a surrogate model for human pCD. The aim 
of this study was to characterize the bacterial 
microbiome structure of dogs suffering from CAF. 
We posit that characterizing the microbiomes of 
CAF dogs will help clarify the pathophysiology 
of CAF and advise on the translational significance 
of CAF as an animal model for pCD.
Results and discussion
CAF is associated with gut microbiota changes
A total of 20 dogs were recruited for this study: eight 
healthy control dogs (HC dogs), and 12 CAF dogs 
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(Table 1). We collected 4–6 fecal samples per dog, 
totaling 70 CAF samples and 38 HC samples. 
Shotgun sequencing of the samples revealed the pre-
sence of the following bacterial phyla (relative abun-
dance indicated as percentage of total 
reads): Firmicutes (48%), Bacteroidetes (31%), 
Proteobacteria (12%), Actinobacteria (7%), and 
Fusobacteria (2%). When we analyzed differences 
in microbial composition between dogs according 
to their disease status, we found slightly lower 
alpha diversity in CAF dogs compared to HC dogs 
(Figure 1A, Shannon diversity, Kruskal–Wallis test, 
p value = .06), similar to previous results with IBD 
dogs.46 As expected, there was also generally lower 
alpha diversity in older dogs compared to younger 
dogs (Spearman correlation, p value = .1). No sig-
nificant differences in alpha diversity were observed 
by weight.
After filtering out low abundance genera (i.e., 
genera not detected four times or more in at least 
20% of the samples), we performed gneiss analysis,47 
which applies the concept of balance trees to 
Table 1. Characteristics of the recruited dogs according to disease status and cluster.
HC dogs (n = 8, 38 
samples)
CAF dogs (n = 12, 70 
samples)
CAF dogs, near cluster (n = 7, 
65 samples)
CAF dogs, far cluster (n = 5, 43 
samples)
Dogs description
Average age (years) ± STDEV 7.3 ± 1.43 4.3 ± 1.28 7.9 ± 1.53 7 ± 0.89
Average weight (kg) ± STDEV 36.9 ± 7.93 41.1 ± 7.31 42.4 ± 9.37 39.2 ± 2.77
Female sex 4 (50%) 3 (25%) 1 (14.3%) 2 (40%)
Number of fistulas
0–2 0 4 3 1
3–5 0 5 3 2
>5 0 3 0 3
Pathology findings
Morphological features ND
Crypt hyperplasia 3 (25%) 1 (14.3%) 2 (40%)
Crypt dilation/distortion (% positive) 8 (66.7%) 5 (71.4%) 3 (60%)
Fibrosis/atrophy (% positive) 8 (66.7%) 5 (71.4%) 3 (60%)
Inflammation ND
Lamina Propria lymphocytes and plasma 
cells (% positive)
3 (25%) 1 (14.3%) 2 (40%)
Lamina Propria Eosinophils (% positive) 4 (33.3%) 2 (28.6%) 2 (40%)
Final diagnosis ND
Normal mucosal (% positive) 3 (25%) 2 (28.6%) 1 (20%)
Lymphoplasmatic inflammatory 
(% positive)
2 (16.7%) 0 2 (40%)
Eosinophilic inflammatory (% positive) 4 (33.3%) 2 (28.6%) 2 (40%)
Mucosal atrophy/fibrosis 
(non-inflammatory) (% positive)
































Figure 1. Analysis of the microbiota composition in samples from CAF dogs and HC dogs. A) Shannon index of alpha diversity for HC 
dogs (green) and CAF dogs (orange). B) Relative abundance of the bacterial taxa found to discriminate between dogs with different 
disease status: HC dogs (green) and CAF dogs (orange); thick black lines indicate mean abundance. T-test, p values are expressed as: 
****<0.0001, ***<0.001, and #0.1 (Corrected for multiple comparisons (5 bacterial taxa found significantly different by disease status) 
using the Bonferroni-Dunn method, with alpha = 0.05).
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compositional data to identify microbial subcommu-
nities that covary with environmental variables. The 
gneiss analysis considers the log-ratio abundances of 
subcommunities within the microbiome to indicate 
taxa whose abundances change relative to other taxa 
with respect to a variable of interest; in our analysis, 
the variable of interest was disease status (CAF ver-
sus HC). We used linear mixed-effect models to 
account for inter-individual microbiome variability 
in this analysis. When we analyzed the microbiomes 
according to disease status, we found that 
Megamonas hypermegale, Megamonas unclassified, 
Bacteroides coprocola, Megamonas funiformis, and 
Bacteroides plebeius were differentially abundant in 
CAF dogs compared to HC dogs (Table 2). We 
further confirmed that there were significant differ-
ences in the proportions of these five bacterial taxa 
between HC dogs and CAF dogs, with lower abun-
dance in CAF dogs (Figure 1B, false discovery rate 
[FDR], t-test). We also applied analysis of the com-
position of microbiomes (ANCOM) to identify dis-
criminant bacterial taxa for CAF dogs versus HC 
dogs. We identified M. funiformis (W = 51), 
M. hypermegale (W = 52), and M. unclassified 
(W = 60) as discriminating between CAF dogs and 
HC dogs. Altogether, these two robust analyses con-
curred that the abundance of Megamonas species can 
discriminate between HC dog samples and CAF-dog 
samples.
Dogs suffering from CAF exhibit a dichotomous 
bacterial community structure
We, next, investigated the microbiome patterns 
further. Using partitioning around medoids with 
the estimation of the number of clusters (PAMK), 
we determined the optimal number of clusters 
(Supplementary Figure 1) based on the Bray 
Curtis dissimilarity index calculated from the rela-
tive abundance of each bacterial taxa (n = 61). 
Clustering results are visualized the with non- 
metric multidimensional scaling (NMDS). As seen 
in Figure 2A, CAF dogs were divided into two 
clusters: healthy-like cluster, referred to hereafter 
as “near cluster,” gathering in close proximity to 
HC dogs; and dysbiotic cluster, referred to hereafter 
as “far cluster,” positioned significantly more dis-
tant from the HC dogs (Bray Curtis distance, 
PERMANOVA, R2 = 0.252, p value = .001. 
Supplementary Figure 2). Although the average 
silhouette width in this analysis indicated a weak 
structure, this differentiation has been repeatedly 
reported in patients suffering from CD.44,48-50 
Taken together, these data suggest that the micro-
biota of CAF dogs can range from one that closely 
resembles that of a healthy individual to a dysbiotic 
microbiota that differs markedly from that of 
a healthy individual, similar what it was been 
observed repeatedly in CD patients.
To identify determinant taxa associated with 
each cluster, we performed additional analyses 
with gneiss and ANCOM. We found that CAF 
dogs belonging to the near cluster had different 
dominance of M. funiformes and Megamonas 
unclassified compared to HC dogs (Table 2). 
Moreover, ANCOM results identified P. copri 
(W = 53) as a bacterial taxon that differentiated 
between CAF dogs belonging to the near cluster 
and HC dogs.
When comparing CAF dogs belonging to the far 
cluster and HC dogs, both gneiss and ANCOM 
identified B. coprocola (W = 52), M. funiformis 
(W = 49), M. hypermegale (W = 48), and 
M. unclassified (W = 52) as distinguishing between 
Table 2. Bacterial taxa with significantly different dominance between samples grouped by disease status or cluster.
Comparison Determinant bacterial taxa gneiss, FDR-corrected p value Group showing increased abundance





HC dogs versus CAF dogs in near cluster Megamonas funiformis 0.01357096 HC dogs
Megamonas unclassified
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the two groups (Table 2). One additional bacterial 
taxon was identified as being differentially domi-
nant between CAF dogs belonging to the far cluster 
and HC dogs only by gneiss: B. plebeius.
We also investigated differences between CAF 
dogs belonging to the near and far clusters. We 
found that the two clusters differed in the domi-
nance of M. hypermegale, M. unclassified, 
B. coprocola, M. funiformis, and B. plebeius 
(Table 2). Moreover, ANCOM results identified 
six bacterial taxa that distinguished between the 
near and far clusters, specifically, B. coprocola 
Figure 2. Analysis of the microbiota clusters. A) NMDS visualization of samples from HC and CAF dogs. Bacterial taxa present were 
quantified by MetaPhlAn, distances were calculated using Bray Curtis dissimilarity index, and samples were plotted based on NMDS. 
Clusters were defined using PAMK and are colored green (HC dogs), orange (CAF dogs in the near cluster) and red (CAF dogs in the far 
cluster). Relative abundance of the bacterial taxa found to discriminate between dogs, separated by cluster assignment: B) Bacterial 
taxa overrepresented in HC dogs or CAF dogs in the near cluster compared to CAF dogs in the far cluster; C) Bacterial taxa 
overrepresented in CAF dogs in the far cluster compared to HC dogs or CAF dogs in the near cluster. Clusters are colored as described 
for panel A, and thick black lines indicate mean abundance. FDR t-test, p values are expressed as: ****<0.0001, ***<0.001, ** <0.005, * 
<0.05, and #0.1 (Corrected for multiple comparisons (8 bacterial taxa found significantly different among clusters and HC) using the 
Bonferroni-Dunn method, with alpha = 0.05).
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(W = 50), B. plebeius (W = 51), Bacteroides vulgatus 
(W = 52), P. copri (W = 53), Megamonas unclassi-
fied (W = 48), and Escherichia coli (W = 48). 
Particularly, we found that the relative abundance 
of six of those bacterial taxa decreased (Figure 2B) 
while two increased (Figure 2C) in the far cluster 
compared to HC dogs and the CAF dogs in the near 
cluster.
Overall, these analyses established that higher 
abundance of Megamonas spp., P. copri, 
B. coprocola, and B. plebeius is associated with 
healthy and healthy-like (near cluster CAF-dog) 
samples. On the other hand, increased abundance 
of E. coli and B. vulgatus is associated with dysbiosis 
(far cluster CAF dogs).
Clinical manifestations of CAF are associated with 
dysbiosis
CAF has a clinical appearance similar to that of 
perianal fistulas in humans, a complication fre-
quently associated with CD. Specifically, dogs suf-
fering from CAF develop epithelial-lined sinus 
tracts around the perianal tissue including super-
ficial, intersphincteric, or intrasphincteric fistulas 
that can extend to the rectal lumen.15,16 These 
ulcerative tracts vary in diameter, depth, and con-
nectivity, and can affect the entire area around the 
anus. These lesions are usually referred to as fistu-
las. The CAF dogs recruited in this study presented 
with varying numbers of fistulas (average, 3.3 ± 1.4. 
Table 1) but no anal sac disease was observed. We 
found that CAF dogs in the far cluster exhibited 
a trend of higher average number of fistulas than 
those in the near cluster (4 vs. 2.87, respectively, 
Figure 3A). Moreover, Helicobacter canis domi-
nance was statistically different between CAF dogs 
according to fistula number (gneiss, FDR corrected 
p value <.0001). To determine the direction of 
dominance, we performed correlation analysis 
between H. canis relative abundance and number 
of fistulas. We found a negative correlation between 
H. canis relative abundance and the number of 
fistulas in CAF dogs (Table 3).
It has been suggested that increased host DNA 
content in fecal samples may be an indicator of 
inflammation-associated shedding of epithelial or 
blood cells. Indeed, a previous study found high 
levels of human DNA in stool samples from pedia-
tric patients with active CD.44 Thus, we determined 
the abundance of dog DNA sequences present in 
each stool sample analyzed as a percentage of total 
reads. We found that samples from CAF dogs con-
tained a higher percentage (mean = 4.09%, mini-
mum = 0.02%, maximum = 44.68%) of host DNA 
sequences than did samples from HC dogs 
(Mean = 0.41%, minimum = 0.02%, maxi-
mum = 2.38%, Mann–Whitney test, p value = .001, 
Figure 3B). There was no significant difference 
between the abundance of host DNA sequences 
recovered in samples from the near versus far clus-
ter. This result suggests that, compared to their 
healthy counterparts, CAF dogs have a higher 
degree of shedding of epithelial or blood cells asso-
ciated with inflammation, similar to what has been 
previously observed in CD humans.
In addition to fistulas, GSD with CAF frequently 
present clinical and histologic evidence of colitis. 
The major microarchitectural changes accompany-
ing colonic inflammation in dogs include crypt 















































Figure 3. Clinical manifestation of CAF. A) The number of fistulas presented by CAF dogs according to cluster (orange, near cluster; red, 
far cluster). B) Percentage of dog DNA reads in metagenomic sequencing samples grouped by disease status. C) Shannon index of 
alpha diversity in samples from HC dogs (green, n = 8) or CAF dogs exhibiting fibrosis (orange pattern, n = 6). T-test, p values are 
expressed as: ****<0.0001, ***<0.001, ** <0.005, * <0.05, and #0.1.
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hyperplasia, dilation/distortion, and mucosal atro-
phy or fibrosis.51 Thus, we also assessed morpho-
logical features and other immune-associated 
inflammatory markers on the colonic mucosa of 
the CAF dogs (Table 1).
First, we observed that there was a positive correla-
tion between histopathology scores and number of 
fistulas (Spearman correlation, p value <.05). Further, 
we found that 75% of the CAF dogs included in this 
study exhibited morphological evidence of either 
cryptal hyperplasia, dilation/distortion, or fibrosis. 
CAF dogs with those major microarchitectural 
changes showed differential dominance of the same 
bacterial taxa that were associated with general CAF 
disease status, namely, Megamonas species 
(M. hypermegale, M. unclassified, and M. funiformis), 
B. plebeius, and B. coprocola (data not shown). In 
addition to these taxa, Ruminococcus torques, known 
to be decreased in CD,44,48,52,53 was also identified as 
a determinant taxon between CAF dogs with major 
microarchitectural changes and HC dogs (gneiss, FDR 
corrected p value <.05). Moreover, we found that 
R. torques relative abundance is negatively correlated 
with microarchitectural changes (Table 3). 
Interestingly, CAF dogs presenting fibrosis (50%) 
exhibited significantly decreased alpha diversity com-
pared to HC dogs (Figure 3C, Shannon diversity, 
Kruskal–Wallis test, p value <.05).
Furthermore, CAF dogs exhibiting major micro-
architectural combined with infiltration of immune 
cells (i.e., eosinophils, lymphocytes, or plasma cells) 
in the lamina propria (41.6%) showed differential 
abundance of Subdoligranulum unclassified and 
Paraprevotella unclassified when compared to CAF 
dogs without those clinical manifestations (gneiss, 
FDR corrected p value = .02). Particularly, those 
bacterial taxa were negatively correlated with both 
major microarchitectural changes and immune cell 
infiltration (Table 3). Recently, depletion of 
Subdoligranulum species in dysbiotic CD patients 
was associated with bile acid dysregulation.50
Based on the presence of major microarchitec-
tural and immune cells in the lamina propria we 
calculated pathology scores as described before.51 
We observed that the pathology scores from CAF 
dogs belonging to the near cluster (median = 2, 
minimum = 0, maximum = 5) were comparable to 
those of the far cluster (median = 3, minimum = 0, 
maximum = 5, Mann–Whitney test, p value >.05).
To investigate whether CAF dogs exhibited periph-
eral signs of inflammation, complete blood counts 
(CBCs) were performed. CBC indicators were within 
the normal range for all tested CAF dogs; thus, no sign 
of serious inflammation or infection was detectable by 
CBC analysis (data not shown). Although hemoglobin 
levels were lower in CAF dogs belonging to the far 
cluster than in those in the near cluster, we did not 
identify any bacterial taxa associated with hemoglobin 
levels, nor with any of the analyzed blood inflamma-
tory markers.
In sum, there is an inverse correlation between 
H. canis abundance and the number of fistulas. In 
addition to the bacterial taxa associated with disease 
status, CAF dogs exhibiting microarchitectural 
changes related to inflammation also exhibit 
decreased R. torques abundance. Furthermore, CAF 
dogs presenting microarchitectural defects combined 
with immune cell infiltration in the lamina propria 
have decreased abundance of Subdoligranulum 
unclassified and Paraprevotella unclassified.
Microbial gene pathways change in accordance with 
disease status
The genomic content of the microbiota was deter-
mined using HUMAnN2.54 After filtering for gene 
Table 3. Bacterial taxa that correlate with clinical manifestations of CAF.






Number of fistulas Helicobacter canis −0.4715 < 0.001 0.00000003
Pathology findings
CAF dogs with a combination of crypt hyperplasia, 
crypt dilation/distortion, and/or fibrosis/atrophy 
(n = 7)
Ruminococcus torques −0.355 0.002 < 0.05
CAF dogs with a combination of microarchitectural 
changes and presence of inflammatory markers 
(n = 5)
Subdoligranulum unclassified −0.1639 0.1751 0.02305158
Paraprevotella unclassified −0.3336 0.0048
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pathways that were not present in at least 5% of the 
samples, we performed clustering analysis on 1,532 
filtered pathways. Clustering of the gene pathway 
abundances separated CAF dogs belonging to 
either the near cluster or the far cluster from HC 
dogs (Figure 4A, PERMANOVA, R2 = 0.19, 
p value = .001).
Random Forest was used to identify microbial 
gene pathways that best distinguished HC dogs 
from CAF dogs, predicting differences with an 
OOB estimate of error rate of 6.48% (Figure 4B). 
As expected, most of the identified gene pathways 
originated from bacterial genera that were found to 
be predictive of disease status, specifically, 
Megamonas, Bacteroides, and Helicobacter.
Altogether, the metabolic capacity of the micro-
biome varied along with disease status or cluster 
assignation. Hence, most of the discriminant gene 
pathways belong exclusively to bacterial taxa 
depleted in CAF dogs. Although it is uncertain 
that this phenomenon causes or is a consequence 
of disease, characterization of these changes will 
enlighten our understanding of the microbial 
dynamics in disease.
Discussion
Our understanding of the pathophysiology of pCD 
is not complete albeit their high prevalence and 
burden for patients with CD. The major challenge 
to study the pathogenesis of this manifestation is 
the absence of relevant animal models. Here, we 
characterized the microbiome of dogs suffering 
from CAF in order to explore the usefulness of 
dogs as models for pCD, a serious complication of 
CD that represents an unmet clinical need.
Other studies have aimed to characterize the 
microbiome composition of dogs with IBD with 
varying symptoms and from different breeds55-58 
and their similarities with those from humans 
with IBD.46 However, this is the first study that 
aims to describe the similarities of dogs suffering 
from a specific clinical manifestation: canine fur-
unculosis (CAF), to compare it to those from 
humans with CD. Moreover, we only included in 
the study German Shepherd Dogs, a breed suscep-
tible to IBD with genetic polymorphisms compar-
able to those found in their IBD human 
counterpart.59,60
Interestingly, we found that similar to the 
microbiome of pediatric44 and adult50 patients 
with IBD, the microbiomes of CAF dogs can be 
either healthy-like or dysbiotic. The most recent 
Human Microbiome Project (HMP) study includ-
ing 132 IBD patients and 2,965 stool samples col-
lected over a year showed the same bi-modal 
microbiome pattern among patients with IBD.50 
Specifically, the authors found that differences 
between dysbiotic and healthy-like microbiomes 
were more pronounced in patients with CD. 
Moreover, dysbiotic microbiomes in patients 
with CD were characterized by depletion of obli-
gate anaerobes and enrichment of facultative- 
anaerobes.50 Similarly, we found that decreased 
abundance of obligate anaerobes such as 
Megamonas species and P. copri and increased 
Figure 4. Microbial gene pathway analysis. A) Bray Curtis dissimilarity index beta diversity plot of dogs samples colored by clustering 
assignation: HC dogs (green) and CAF dogs belonging to the near (orange) or far (red) cluster. Bacterial pathways were quantified by 
HUMAnN2 and samples were plotted based on principal component analysis. B) The top 20 gene pathways that most strongly 
distinguish between CAF-dog samples and HC dog samples, identified using Random Forest.
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abundance of facultative-anaerobes such as E. coli 
distinguish between samples from CAF dogs with 
a dysbiotic microbiome and those from HC dogs.
Megamonas is a common gut commensal 
microbe of carnivore animals. Increased abundance 
of Megamonas has been found in healthy cats61 and 
in dogs consuming inulin-rich diets.62 Few studies 
have shown the relevance of Megamonas in human 
health.63,64 Megamonas species are important pro-
pionate and acetate producers.65,66 Thus, based on 
these results, a greater emphasis on Megamonas, 
and its potential impact on gastrointestinal health, 
may be justified in the future.
Moreover, as seen in CAF dogs with a dysbiotic 
microbiome, pediatric patients with CD exhibiting 
a dysbiotic microbiome harbored significantly less 
abundance of P. copri compared to healthy control 
individuals.44 In the HMP study, however, abun-
dance of P. copri was not significantly different 
between CD patients and healthy controls but the 
latter showed an expansion and relaxation of 
P. copri abundance over time. This organism is of 
particular interest given that it has been long asso-
ciated with health but also more recently with new- 
onset of rheumatoid arthritis.67 Thus, further 
research on the role of P. copri in IBD is needed.
In the HMP study, the depleted anaerobe species 
in the far dysbiotic cluster were Faecalibacterium 
praustnizii and Ruminococcus hominis.50 Thus, 
although depleted bacterial species might not over-
lap between CAF and CD, we do observe 
a microbiome composition trend, namely 
a dysbiotic microbiome characterized by depletion 
of obligate anaerobes, that is similar between the 
two diseases.
On the other hand, we did find that increased 
abundance of E.coli overlaps between CAF and CD. 
Increased abundance of Proteobacteria, specifically 
E. coli, has been definitively demonstrated in 
patients with CD.68–72 In addition, the HMP study 
reported that CD patients exhibiting a dysbiotic 
microbiome harbor increased abundance of 
E. coli.50
We also found an enrichment of Bacteroides 
vulgatus in the far dysbiotic cluster. Increased 
abundance of B. vulgatus has previously been 
observed in dogs46,56-58 and in patients with 
IBD.73,74 Bacteroides species, namely B. vulgatus, 
are thought to be responsible for the development 
of inflammation and aberrant immune response in 
the gut.75–79 Therefore, these two strains seemed to 
be favored in the context of CAF and CD.
Concomitantly with what has been observed in 
patients with CD, we found that dysbiotic micro-
biomes are associated with host independent mar-
kers of disease.50 Here, CAF dogs with dysbiotic 
microbiomes tend to have a higher number of 
fistulas. We also found that markers of inflamma-
tion such as microarchitectural changes and 
immune cell infiltration in the lamina propria 
were negatively correlated with the abundance of 
Ruminococcus torques, Subdoligranulum unclassi-
fied, and Paraprevotella unclassified. Of note, 
Ruminococcus torques is a butyrate-producing 
Clostridia shown to induce anti-inflammatory 
activity and is known to be decreased in 
CD.44,48,52,53 Similarly, the HMP study50 estab-
lished that Subdoligranulum species – also with 
butyrate-producing capacities – were both reduced 
in dysbiotic CD patients and associated dysregula-
tion of IBD-linked metabolites (i.e., bile acids, car-
nitines, and polyunsaturated fatty acids).
In sum, we found that dogs suffering from CAF 
exhibit gut bacterial community structures that 
resemble those observed in CD patients. 
Moreover, we found overlapping bacteria species 
and their metabolic capacity associated with dys-
biosis in both CAF and human CD. Therefore, we 
propose to use dogs suffering from CAF as 
a surrogate model to: (1) study pCD to further 
elucidate the role of the microbiome in this clinical 
complication, and (2) explore the pre-clinical effi-
cacy of microbiome-centered therapeutics to 
treat pCD.
Methods and materials
Subjects and sample collection
All dogs in this study were GSD that had not 
received antibiotic treatment within the preceding 
3 months and were treated with a special diet (novel 
protein or hypoallergenic) for at least 8 weeks with-
out clinical response. CAF dogs were recruited 
from Cummings School of Veterinary Medicine at 
Tufts University. Inclusion criteria included 
German Shepard dogs with a clinical diagnosis of 
perianal fistulas with clinical signs of tenesmus, 
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dyschezia, and partial or complete relapse from 
cyclosporine A therapy. HC dogs were selected 
based on the absence of perianal fistulas, nonexis-
tence of diarrhea or adverse gastrointestinal symp-
toms, and lack of immunosuppressant treatment. 
Dog information including age, weight, gender, 
number of fistulas, treatment, and antibiotic usage 
was obtained from clinical records.
Naturally passed feces were collected daily for 
a period of 1 week from eight HC dogs and from 
12 CAF dogs. Dog owners were provided with 
tubes (OMNI•gene-GUT| OMR-200, DNAgenotek, 
Canada) for sample collection and were instructed to 
place a clean pad on the surface before dogs’ bowel 
movement to avoid sample contamination from soil, 
grass, or other surfaces. Samples were freshly col-
lected into the tubes provided. Samples were stored 
at room temperature until they were delivered at the 
next clinical appointment, which occurred within 
2 weeks of sampling. During that next appointment, 
biopsies from the distal colon and blood samples 
were obtained from all CAF dogs for histopathologi-
cal analysis and CBC, respectively. To determine 
colonic inflammation, an experienced pathologist 
blind-scored the biopsies based on the infiltration 
of eosinophils, lymphocytes, or plasma cells in the 
lamina propria and morphological changes, includ-
ing crypt dilation/distortion, fibrosis/atrophy, or 
crypt hyperplasia, as previously described.80
DNA isolation and sequencing
DNA isolation was performed using the 
MagAttract PowerSoil DNA Kit (Qiagen, # 27100- 
4-EP) on Eppendorf epMotion 5075 liquid handlers 
following the manufacturer’s instructions. DNA 
sequencing libraries were prepared using the 
Nextera XT DNA Library Preparation Kit 
(Illumina, #FC-131-1096) and were sequenced on 
the Illumina NextSeq 500 platform as 150-nt 
paired-end reads. We obtained an average of 
3.8 M reads per sample (minimum: 1 M reads and 
maximum: 7.7 M reads). Read data were quality 
trimmed and filtered of host DNA using 
KneadData (https://bitbucket.org/biobakery/knead 
data/wiki/Home) against a prebuilt bowtie2 index 
for Canis familiaris reference genome, build 3.1.
Metagenomic profiling
Community composition was profiled using 
MetaPhlan281 to determine the per sample relative 
abundance of species composition of bacterial, fun-
gal, parasitic, and viral genomes per sample. Then, 
to assess the content of metabolic and functional 
genes and metabolic pathways we used 
HUMAnN2.54
Statistical analysis
For analysis, we considered only taxa that were 
detected in at least 10% of samples and had 
a relative abundance of at 0.2% or greater in at 
least one sample. Community patterns were ana-
lyzed using partitioning around medoids with the 
estimation of the number of clusters (PAMK) to 
find the optimal number of clusters as performed 
previously44 and visualized after multidimensional 
scaling (MDS). Clustering analyses and visualiza-
tions were performed in Phyloseq 1.26.1 and the 
R package cluster v1.4–1 to estimate microbiome 
patterns using PAMK with optimum average sil-
houette width.82,83 Briefly, the PAM algorithm is 
based on the search for “k” representative objects or 
k-medoids among the observations of the data set. 
In k-medoids clustering, each cluster is represented 
by one of the data point in the cluster. These points 
are named cluster medoids. After finding a set of 
k-medoids, clusters are constructed by assigning 
each observation to the nearest medoid. To esti-
mate the optimal number of clusters, we estimated 
the average silhouette method. Here, we compute 
the PAM algorithm using different values of clus-
ters k. Next, the average cluster silhouette is calcu-
lated according to the number of clusters. A high 
average silhouette width indicates a good cluster-
ing. The optimal number of clusters k is the one 
that maximizes the average silhouette over a range 
of possible values for k.
Shannon diversity index (alpha diversity) and 
Bray Curtis dissimilarity (beta diversity) were calcu-
lated using QIIME2 1.8.9. To assess the significance 
of differences in diversity metrics between samples 
according to either disease status or cluster assigna-
tion, we used Kruskal–Wallis, PERMANOVA, 
ADONIS, and Mantel tests. Determinant bacterial 
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species were identified by the robust algorithms 
gneiss47 and ANCOM84 implemented in QIIME2.
In gneiss, we used linear-mixed models (LME) to 
account for the random effect of patients with mul-
tiple samples. LME are used to test the relationship 
between a single response variable and one or more 
independent variables, where observations are 
made across dependent samples. We then evaluated 
the correlations (with FRD correction) of 61 bac-
terial taxa with each variable separately, specifically 
disease status (CAF vs HC), cluster assignation 
(CAF near cluster, CAF far cluster, and HC), or 
clinical manifestations (number of fistulas, crypt 
hyperplasia, crypt dilation/distortion, fibrosis/atro-
phy). To understand the direction of dominance 
found in gneiss we performed Spearman correla-
tions of the determinant bacterial taxa with the 
clinical manifestation of interest.
Additionally, we use ANCOM adjusting for 
dependent repeated measurements.84 For ANCOM, 
we analyzed 61 bacterial taxa, and only bacterial taxa 
reporting W > 45 were considered significant.
Finally, we used Random Forest (R package, 
randomForest 4.6–14),6,8a supervised learning algo-
rithm, to identify gene pathways that discriminated 
samples by disease status as previously described.44
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